Oxaliplatin is a third generation diaminocyclohexane (DACH) platinum compound that forms mainly intrastrand links between two adjacent guanine residues or a guanine and an adenine, disrupting DNA replication and transcription ([Fink *et al*, 1997](#bib20){ref-type="other"}). Although the related platinum compounds, cisplatin and carboplatin, are generally ineffective in the treatment of colorectal cancer, oxaliplatin has been shown to be effective in the treatment of this disease and it is commonly used to treat patients unresponsive to 5-fluorouracil (5FU) based therapy. However, the details underlying the cytotoxic effects of oxaliplatin remain poorly understood.

Exposure of tumour cells to several chemotherapeutic agents, including oxaliplatin, has been shown to induce programmed cell death or apoptosis ([Searle *et al*, 1975](#bib46){ref-type="other"}; [Lowe and Lin, 2000](#bib32){ref-type="other"}; [Gourdier *et al*, 2002](#bib23){ref-type="other"}; [Johnstone *et al*, 2002](#bib27){ref-type="other"}). In mammalian cells, the signalling cascades leading to apoptosis can be divided into two broad groups. The intrinsic pathway is characterised by the central role of the mitochondria in the initiation of the caspase cascade executing the apoptotic program ([Desagher and Martinou, 2000](#bib17){ref-type="other"}). Pro- and antiapoptotic Bcl-2 family members play a pivotal role in the intrinsic apoptotic cascade ([Narita *et al*, 1998](#bib39){ref-type="other"}; [Gross *et al*, 1999](#bib24){ref-type="other"}). Upon exposure to some apoptotic stimuli, proapoptotic Bcl-2 family members such as Bax, which normally reside in the cytosol, are relocated to the outer mitochondrial membrane where they lead to the release of apoptotic factors from the mitochondria and ultimately to caspase activation and an apoptotic cell death ([Li *et al*, 1997](#bib30){ref-type="other"}; [Zou *et al*, 1997](#bib55){ref-type="other"}). The tumour suppressor gene p53 has been shown to directly regulate the expression levels of Bax ([Miyashita and Reed, 1995](#bib38){ref-type="other"}), and both p53 and Bax have been shown to be important determinants of the cellular response to chemotherapeutic agents ([Bunz *et al*, 1999](#bib11){ref-type="other"}; [Zhang *et al*, 2000](#bib54){ref-type="other"}). In the *extrinsic* pathway, however, caspase activation is initiated by death receptors on the cell surface ([Ashkenazi and Dixit, 1998](#bib6){ref-type="other"}). Chemotherapeutic agents are known to induce apoptosis by either of these two mechanisms ([Lowe and Lin, 2000](#bib32){ref-type="other"}; [Johnstone *et al*, 2002](#bib27){ref-type="other"}).

While significant progress has been made in the identification of markers predicting response to 5FU and CPT-11, two additional chemotherapeutic agents commonly used for colorectal cancer treatment ([Augenlicht *et al*, 1997](#bib7){ref-type="other"}; [Bunz *et al*, 1999](#bib11){ref-type="other"}; [Salonga *et al*, 2000](#bib44){ref-type="other"}; [Arango and Augenlicht, 2001](#bib2){ref-type="other"}; [Arango *et al*, 2001](#bib3){ref-type="other"}; [2003](#bib4){ref-type="other"}), there is great need for markers that allow discrimination of tumours that vary in their sensitivity to oxaliplatin. The tumour suppressor p53 has a pivotal role in determining the cellular sensitivity to a number of chemotherapeutic agents, including 5FU and CPT-11 ([Bunz *et al*, 1999](#bib11){ref-type="other"}; [Arango *et al*, 2001](#bib3){ref-type="other"}; [2003](#bib4){ref-type="other"}; [Magrini *et al*, 2002](#bib34){ref-type="other"}). In this study we investigated the potential of this genetic marker to predict response to oxaliplatin *in vitro*. Previous studies have shown that simultaneous analysis of multiple independent markers capable of predicting response to chemotherapy significantly improves the accuracy of the predictions ([Salonga *et al*, 2000](#bib44){ref-type="other"}; [Arango *et al*, 2001](#bib3){ref-type="other"}). cDNA microarray analysis allows the assessment of the level of expression of thousands of genes simultaneously, and its potential to predict response of tumour cells to chemotherapeutic agents has been recently demonstrated ([Scherf *et al*, 2000](#bib45){ref-type="other"}; [Kihara *et al*, 2001](#bib28){ref-type="other"}; [Zembutsu *et al*, 2002](#bib53){ref-type="other"}; [Mariadason *et al*, 2003](#bib37){ref-type="other"}). Therefore, we hypothesised that the expression profile of untreated tumour cells could be used to predict sensitivity to oxaliplatin, and used a leave-one-out cross-validation approach to formally demonstrate the accuracy of this approach in a panel of 30 colorectal cancer cell lines.

MATERIALS AND METHODS
=====================

Cell culture
------------

HCT116 colon carcinoma cells and isogenic derivatives with a targeted inactivation of p53 or Bax ([Bunz *et al*, 1998](#bib10){ref-type="other"}; [Zhang *et al*, 2000](#bib54){ref-type="other"}) were a gift of Dr Vogelstein (Johns Hopkins University School of Medicine). Cells were maintained in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 1 × antibiotic/antimycotic (100 U ml^−1^ streptomycin sulphate, 100 U ml^−1^ penicillin G sodium and 0.25 *μ*g ml^−1^ amphotericin B), 100 *μ*[M]{.smallcaps} nonessential amino acids and 10 m[M]{.smallcaps} HEPES buffer solution (all from Invitrogen Corporation, Carlsbad, CA, USA).

Cell cycle and apoptosis
------------------------

For analysis of cell cycle, 2 × 10^5^ HCT116 cells were seeded on six-well plates in triplicate and allowed to attach for 24 h. For time-response studies cells were treated with 5 or 10 *μ*[M]{.smallcaps} oxaliplatin (supplied by Sanofi-Synthelabo, New York, NY, USA) for 12, 24, 48 and 72 h. For concentration--response experiments, cells were treated for 72 h with 5, 10, 15, 20, 25 and 50*μ*[M]{.smallcaps} oxaliplatin. Both attached and floating cells were harvested, washed twice with 2 ml of PBS and resuspended in PBS containing 50 *μ*g ml^−1^ propidium iodine (PI), 0.1% sodium citrate and 0.1% Triton X-100. Cells were stained overnight at 4°C and a minimum of 10 000 cells analysed for DNA content using a Becton Dickinson FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). The proportion of cells in G0/G1, S phase and G2/M were quantified using ModFit 2.0 (Verity Software House, Topsahm, ME, USA). Apoptosis induced by oxaliplatin treatment was assessed by the nuclear morphology of floating cells. HCT116 cells (1.6 × 10^6^) were seeded on T75 culture flasks and allowed to attach to the substrate for 24 h before exposure to 25 *μ*[M]{.smallcaps} oxaliplatin for 48 h. Floating cells were collected, pelleted and re-suspended in 1 *μ*[M]{.smallcaps} DAPI (Sigma, St Louis, MO, USA) in PBS. Micrographs of DAPI stained nuclei were captured with a SPOT RT Diagnostic Instruments CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA) attached to a BX60 Olympus fluorescence microscope (Olympus, Melville, NY, USA). Quantification of apoptosis was carried out by PI staining and flow cytometric analysis of the proportion of cells with a subdiploid content of DNA using WinList 2.0 (Verity Software House, Topsahm, ME, USA). In some experiments, cell cultures were preincubated with 2 *μ*g ml^−1^ anti-Fas receptor antibody ZB4 (Upstate Biotechnology, Lake Placid, NY, USA) or 1 *μ*g ml^−1^ anti-Fas ligand antibody NOK-1 (BD Biosciences Pharmingen, San Diego, CA, USA) for 1 h before oxaliplatin cotreatment. Some HCT116 cultures were coincubated with the pan-Caspase inhibitor z-VAD-fmk (Calbiochem, La Jolla, CA, USA) at the final concentrations indicated in the text.

Caspase 3 activation
--------------------

HCT116 cells (2 × 10^5^) were seeded on six-well plates in triplicate, allowed to attach for 24 h, and then treated with 25 *μ*[M]{.smallcaps} oxaliplatin. After 72 h of treatment, floating cells were collected and pooled with the attached cells harvested by trypsinisation. Cells were washed with PBS, resuspended in CytoFix/CytoPerm (Pharmingen, San Diego, CA, USA), incubated for 30 min on ice and then washed with Perm/Wash buffer (Pharmingen, San Diego, CA, USA) and resuspended in 100 *μ*l of Perm/Wash buffer. In total, 20 *μ*l of phycoerythrin (PE)-conjugated anti-active caspase-3 (Pharmingen, San Diego, CA, USA) were added and cells were incubated at 4°C in the dark for 30 min, washed with Perm/Wash buffer and resuspended in 400 *μ*l of Perm/Wash buffer. Samples were analysed using a Becton Dickinson FACScan, measuring logarithmic PE fluorescence in the FL-2 channel in a minimum of 10 000 cells.

Western blotting
----------------

HCT116 cells seeded in 75 cm^2^ flasks were treated with 10 *μ*[M]{.smallcaps} oxaliplatin for 0, 6, 12, 16 or 24 h and then rinsed with PBS twice, harvested and resuspended in 300 *μ*l of RIPA lysis buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 [M]{.smallcaps} NaCl, 0.01 [M]{.smallcaps} sodium phosphate pH 7.2, 2 m[M]{.smallcaps} EDTA, 50 m[M]{.smallcaps} sodium fluoride, 0.2 m[M]{.smallcaps} sodium vanadate and 100 U ml^−1^ aprotinin). The cell suspension was vortexed and kept on ice for 30 min before cell debris was pelleted and the supernatant transferred to a new tube. SDS--polyacrylamide gel electrophoresis sample loading buffer (6 ×) was added to 20 *μ*g aliquots and loaded on 15% tris-HCl precast gels (BioRad, Hercules, CA, USA). Fractionated proteins were transferred to a PVDF membrane (Amersham, Piscataway, NJ, USA) and blocked with 10% nonfat milk for 1 h. Membranes were then probed at room temperature with the appropriate primary antibody in 5% nonfat milk for 1 h with the following antibodies: anti-p53 (Santa Cruz, DO-1, 1/7000), anti-p21^Cip1/WAF1^ (Santa Cruz, H-164, 1/200) and anti-*β*-actin (Sigma, clone AC74, 1/1000). Membranes were washed three times with washing buffer (PBS with 0.1% Tween 20) and then probed with the appropriate peroxidase-conjugated secondary antibody for 1 h (all from Roche Diagnostics/Boehringer Mannheim Corporation, Indianapolis, IN, USA). The secondary antibody was washed three times with washing buffer and the signal was developed using ECL Plus Western Blotting Detection Method (Amersham, Piscataway, NJ, USA). Detection was carried out using a Storm PhosphorImager and quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). Protein levels were standardised using the signal from the *β*-actin probe.

Immunofluorescence analysis
---------------------------

Cells were cultured overnight on preferred glass coverslips (Fisher, Pittsburgh, PA, USA), and then treated with 10, 20 or 50 *μ*[M]{.smallcaps} oxaliplatin. The cells were fixed for 15 min in 4% paraformaldehyde (Electron Microscopy Services, Ft Washington, PA, USA), permeabilised with 0.5% Triton X-100/PBS for 5 min and then incubated for 1 h in a 1% BSA/PBS blocking solution. To detect BAX, cells were incubated for 3 h with a rabbit polyclonal IgG that recognised the N-terminal region (Upstate Biotechnology, Lake Placid, NY, USA; 1 : 100 dilution), followed by exposure to a goat Cy3-conjugated anti-rabbit secondary antibody (Amersham, Piscataway, NJ, USA). To detect mitochondria, a mouse monoclonal Hsp60 antibody was used (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1 : 200), the binding of which was detected by a goat anti-mouse FITC-conjugated secondary antibody (Roche Diagnostics/Boehringer Mannheim Corporation, Indianapolis, IN, USA). Cytochrome *c* was detected utilising a mouse monoclonal anti-cytochrome *c* IgG (Pharmingen, San Diego, CA, USA; 1 : 200) followed by exposure to a goat anti-mouse Cy5-conjugated secondary antibody (Amersham Biosciences, Piscataway, NJ, USA). All secondary antibodies were used at a dilution of 1 : 200 for 1 h. All washes were performed with PBS. To visualise nuclei, cells were stained with DAPI (Sigma, St Louis, MO, USA; 4′,6-diamidino-2-phenylindole). Fluorescent images were captured with a SPOT RT Diagnostic Instruments CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA) attached to a BX60 Olympus fluorescence microscope (Olympus, Melville, NY, USA). The proportion of apoptotic cells was quantified by scoring the number of cells simultaneously exhibiting Bax relocalisation and cytochrome *c* release in 200 cells.

Growth/cytotoxicity assay
-------------------------

The concentration of oxaliplatin resulting in 50% inhibition of control growth (GI~50~) in response to oxaliplatin was calculated using the sulphorhodamine B method according to the protocol used by the NCI *in vitro* Anticancer Drug Discovery Screen Program ([Skehan *et al*, 1990](#bib49){ref-type="other"}). Ten thousand cells per well were seeded in 96-well plates and 24 h later exposed to 0, 0.0125, 0.025, 0.125, 0.25, 1.25, 2.5, 6.25, 12.5, 25, 50 and 125 *μ*[M]{.smallcaps} oxaliplatin for 72 h. The GI~50~ concentrations were calculated as described ([Skehan *et al*, 1990](#bib49){ref-type="other"}; [Arango *et al*, 2003](#bib4){ref-type="other"}; [Mariadason *et al*, 2003](#bib37){ref-type="other"}) using Prism 3.0 software (GraphPad, San Diego, CA, USA).

Clonogenic assay
----------------

One million cells were seeded in T25 flasks and 24 h later exposed to 0, 2.5, 3, 3.5 or 4 *μ*[M]{.smallcaps} oxaliplatin for 9 h. Cells were then trypsinised and 500 cells reseeded in six-well plates in triplicate. Colonies were allowed to form for 2 weeks and then plates were washed and air-dried. Colonies were stained with 0.1% crystal violet, washed three times with distilled water, and air-dried. Plates were scanned using a Perfection 1250 scanner (Epson America Inc., Long Beach, CA, USA) and the number of colonies quantified using Total Lab 1.1 software (Nonlinear Dynamics, Durham, NC, USA).

Assessment of p53 status
------------------------

The mutational status of the 30 colorectal cancer cell lines in the panel used has been previously reported ([Mariadason *et al*, 2003](#bib37){ref-type="other"}). Sequencing of the hotspots for p53 mutations (exons 5--8) in T84 cells found no mutations ([Mariadason *et al*, 2003](#bib37){ref-type="other"}). Moreover, Western blot analysis demonstrated that T84 cells have low basal p53 levels, which is characteristic of colorectal cancer cells with a wild-type p53 gene. However, subsequent analyses showed that, unlike other wild-type p53 cell lines in the panel, T84 cells failed to upregulate the p53 target gene p21^Waf1/Cip1^ in response to cytotoxic insult (5 and 50 *μ*[M]{.smallcaps} 5-FU for 24 h -- not shown). We, therefore, sequenced the remaining of the p53 coding sequence in this cell line and found a missense mutation in exon 4 (codon 60, CCA → CTA; Pro → Leu). Moreover, this mutation has previously been identified in human malignancies, further suggesting that this mutation disrupts p53 function (<http://p53.curie.fr>). The p53 primers used in the PCR reactions were exon 2: CGACTGTCCAGCTTTGTGC and CCCGTGACTCAGAGAGGACT; exon 2: GGGTTGGAAGTGTCTCATGC and TCCCACAGGTCTCTGCTAGG; exon 3: CAGTCAGATCCTAGCGTCGAG and AGCCCAACCCTTGTCCTTAC; exon 4: CCTCTGACTGCTCTTTTCACC and AGAAATGCAGGGGGATACG; exon 9: GCAGTTATGCCTCAGATTCACT and AACTTTCCACTTGATAAGAGGTC; exon 10: GTACTGTGAATATACTTACTTCT and CCTATGGCTTTCCAACCTAGGAA; exon 11: TTAGGCCCTTCAAAGCATTGGT0 and CACCTATTGCAAGCAAGGGTTCA.

Microarray analysis
-------------------

The expression profile of the same panel of 30 colorectal cancer cell lines was assessed in using 9216-sequence cDNA microarrays from the Albert Einstein Cancer Center Facility as previously described ([Mariadason *et al*, 2003](#bib37){ref-type="other"}). For each cell line, hybridisations were carried out in duplicate starting from RNA isolated from independent cultures. For each set of replicates, the mean expression value for each sequence was determined and entered into a final database for further analyses. The expression data for the 3725 sequences with a significant level of expression (defined as signal\>background plus two standard deviations in the Cy5 and/or Cy3 channel) in at least one replicate for all 30 cell lines was used in subsequent analyses. All the databases are available on our website ([www.augenlichtlab.com](http://www.augenlichtlab.com)).

'Leave-One-Out' cross-validation analysis
-----------------------------------------

All leave-one-out analyses ([Efron and Tibshirani, 1993](#bib18){ref-type="other"}) were performed using genes that showed a significant level of expression above background in each of the 30 cell lines (3725 of the 9216 genes on the arrays). First, from the 30 cell lines, cell line 1 was removed from consideration, leaving 29 cell lines for analysis. For these 29 cell lines, the Pearson correlation between the level of expression of each of the 3725 genes and the percentage of apoptosis induced by 10 *μ*[M]{.smallcaps} oxaliplatin was computed, and the *N* genes highest absolute value correlations (i.e., corresponding to *N* genes) were selected. *N* was varied from the 10 to 200 best-correlated genes. As a control, *N* randomly selected genes were also analysed. To reduce the number of genes to a smaller set of variables, principal components analysis (PCA) was performed. PCA enables a large number of variables to be reduced to linear combinations of variables that can be used to predict an outcome. From the PCA, the principal components (PCs) having the 10 largest eigenvalues were selected. In general, these 10 PCs accounted for approximately 60% of the variance in the selected genes. Next a multiple regression model was developed using the 10 PCs to predict apoptosis, based on the 29 cell lines in the analysis. Once the regression equation was derived, the 10 PCs corresponding to the 'left out' cell line were computed and substituted into the derived regression equation to yield a prediction of apoptosis in the left out cell line. Thus, the final results for this first leave-one-out procedure were the predicted value of apoptosis for the left out cell line (*y*~1~^\*^) and the observed value (*y*~1~).

After this first leave-one-out procedure was completed, the left out cell line was replaced in the data set, and cell line 2 was removed, once again leaving 29 cell lines in the data set with 1 cell line left out. The entire procedure was repeated for all 30 cell lines so that the final result was a set of predicted apoptosis values for each cell line that had been left out and the corresponding observed value. Each of these 30 leave-one-out procedures yielded 30 pairs of predicted and observed apoptosis values: *y*~1~^\*^, *y*~1~, *y*~2~^\*^, *y*~2~, ..., *y*~30~^\*^, *y*~30~.

To determine how well a given regression model predicted observed apoptosis in the left out cell line, the natural log of observed apoptosis (ln(*y*~i~)) was plotted as a function of the natural log of the predicted value (ln(*y*~i~^\*^)), and a simple linear regression was constructed. The purpose of this regression analysis was to determine whether the predicted and observed values obeyed the equation *y*~i~=*y*~i~^\*^ (i.e., whether the points fall on the line of equality). If the prediction rule is true, then the observed and predicted values would be equal or nearly equal. The measure of linear fit was *r*, and the hypothesis of falling on the line of equality was tested by comparing the slope to unity and *y* intercept to zero.

RESULTS
=======

Oxaliplatin induces a G2/M cell cycle arrest and apoptosis
----------------------------------------------------------

Exposure of an asynchronous culture of HCT116 colon carcinoma cells to clinically achievable concentrations ([Ehrsson *et al*, 2002](#bib19){ref-type="other"}; [Tassone *et al*, 2002](#bib50){ref-type="other"}) of the platinum compound oxaliplatin resulted in a significant time- and concentration-dependent accumulation of cells in the G2/M phases of the cell cycle and a reduction of cells in S phase ([Figure 1A--D](#fig1){ref-type="fig"}Figure 1Effects of oxaliplatin on cell cycle. The cell cycle distribution of HCT116 cells was determined after, (**A**) exposure to 5 *μ*[M]{.smallcaps} oxaliplatin for different times, and (**B**) treatment for 72 h with different concentrations of oxaliplatin. Representative experiments are shown. In panels (**C** and **D**) the number of cells in G0/G1, S phase and G2/M were quantified by PI staining and flow cytometric analysis. Mean of three experiments is shown.). These effects of oxaliplatin on cell cycle progression of proliferating HCT116 cells were accompanied by a significant proportion of cells showing signs of an apoptotic death, which was confirmed by the characteristic morphological changes observed in DAPI-stained nuclei of oxaliplatin-treated cells ([Figure 2A and B](#fig2){ref-type="fig"}Figure 2Induction of apoptosis by oxaliplatin. (**A**) Nuclear morphology of DAPI stained untreated HCT116 cells and (**B**) floating cells from cultures treated with 10 *μ*[M]{.smallcaps} oxaliplatin for 48 h. The number of apoptotic cells was quantified by PI staining and flow cytometric analysis in cultures treated with 5 or 10 *μ*[M]{.smallcaps} oxaliplatin for different times (**C**) and with different concentrations after 72 h of treatment (**D**). Mean of three experiments±s.e. of the mean is shown in (**C** and **D**). ^\*^*P*\<0.05 and ^\*\*^*P*\<0.005 (Student\'s *t*-test).). Quantification of the proportion of apoptotic cells by PI staining and flow cytometric analysis demonstrated that exposure of HCT116 cells to clinically achievable concentrations of oxaliplatin resulted in a significant time-dependent induction of apoptosis ([Figures 1A](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"}) and that the proportion of apoptotic cells was concentration-dependent ([Figures 1B](#fig1){ref-type="fig"} and [2D](#fig2){ref-type="fig"}).

The apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria, cytochrome *c* release and caspase 3 activation
------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the molecular cascade of events following exposure to oxaliplatin, we utilised HCT116 cells, which have a wild-type p53 gene and express a functional Bax protein. Immunofluorescent staining of Bax in untreated HCT116 cells demonstrated a diffuse cytoplasmic localisation of Bax in most cells ([Figure 3A](#fig3){ref-type="fig"}Figure 3Oxaliplatin induced apoptosis is characterised by Bax relocalisation and cytochrome *c* release. (**A**) Immunofluorescent staining with a Bax antibody demonstrating diffuse cytoplasmic staining in the majority of the cells in untreated cultures is shown. Exposure to 10 *μ*[M]{.smallcaps} oxaliplatin for 24 h resulted in a significant proportion of cells exhibiting punctate Bax staining (white arrowheads) consistent with its mitochondrial localisation (see Results). Cytochrome *c* was confined to the mitochondria in the majority of untreated cells. Oxaliplatin treatment resulted in a significant increase in the number of cells displaying a diffuse cytosolic staining of cytochrome *c* (yellow arrowheads). (**B**) Fold induction in the number of cells exhibiting simultaneous Bax relocalisation and cytochrome *c* release in cultures treated with 50 *μ*[M]{.smallcaps} oxaliplatin for various times (mean of at least two experiments±s.e.). (**C**) Treatment of HCT116, RKO, RW2982 and SW403 cells with different concentrations of oxaliplatin for 24 h resulted in a significant concentration-dependent increase in the number of cells showing Bax and cytochrome *c* re-localisation. ^\*^*P*\<0.01 (Student\'s *t*-test).). In agreement with a low incidence (\<1%) of spontaneous apoptosis in untreated cultures (see [Figure 2C](#fig2){ref-type="fig"}), a small proportion of cells showed punctate Bax staining that was demonstrated to localise to the mitochondria by co-staining with Hsp60, a heat shock protein with mitochondrial localisation ([Supplementary material Figure 1](#sup1){ref-type="other"}). However, exposure of HCT116 cells to 10 *μ*[M]{.smallcaps} oxaliplatin resulted in a significant (*P*\<0.001) increase in the number of cells that exhibited a mitochondrial pattern of Bax staining (white arrowheads in [Figure 3A](#fig3){ref-type="fig"}). Translocation of Bax to the mitochondria has been implicated in the formation of the permeability transition pore and cytochrome *c* release from the mitochondria into the cytoplasm ([Narita *et al*, 1998](#bib39){ref-type="other"}; [Gross *et al*, 1999](#bib24){ref-type="other"}). Nonapoptotic untreated HCT116 cells exhibited a mitochondrial localisation of cytochrome *c* ([Figure 3A](#fig3){ref-type="fig"}). However, oxaliplatin treatment resulted in an increase in the number of cells showing a diffuse cytoplasmic cytochrome *c* immunostaining (yellow arrowheads in [Figure 3A](#fig3){ref-type="fig"}). The observed relocalisation of Bax and cytochrome *c* following treatment of HCT116 cells with oxaliplatin was concurrent ([Figure 3A](#fig3){ref-type="fig"}) and time- and concentration-dependent ([Figure 3B and C](#fig3){ref-type="fig"}). Extension of these analyses to other colorectal cancer cell lines showed that exposure of RKO, RW2982 and SW403 cells to 10, 20 or 50 *μ*[M]{.smallcaps} oxaliplatin resulted in a significant (*P*\<0.01) increase in the number of cells showing Bax/cytochrome *c* re-localisation ([Figure 3C](#fig3){ref-type="fig"}).

Cytoplasmic cytochrome *c* has been shown to bind to other components of the apoptosome, resulting in caspase activation ([Liu *et al*, 1996](#bib31){ref-type="other"}; [Zou *et al*, 1997](#bib55){ref-type="other"}). A time-dependent Caspase 3 activation was demonstrated in oxaliplatin-treated cells by immunostaining with a fluorescently labelled antibody that binds specifically to active Caspase 3, and quantified using flow cytometry ([Figure 4A](#fig4){ref-type="fig"}Figure 4Caspase 3 activation in oxaliplatin treated cells. (**A**) FACS analysis of HCT116 cells stained with a PE-conjugated antibody specific to active Caspase 3 demonstrates that oxaliplatin treatment induces a time-dependent increase of active Caspase 3. (**B**) Oxaliplatin-induced apoptosis was abrogated in a dose-dependent manner by the caspase inhibitor z-VAD-fmk. Mean of three experiments±s.e. of the mean.). In agreement with this observation, treatment of HCT116 cells with oxaliplatin in the presence of different concentrations of z-VAD-fmk, a pan-caspase inhibitor, reduced oxaliplatin-induced apoptosis in a concentration-dependent manner ([Figure 4B](#fig4){ref-type="fig"}).

Targeted inactivation of Bax decreased the apoptotic response to oxaliplatin
----------------------------------------------------------------------------

The cellular translocation of Bax to the mitochondria observed in HCT116 cells following exposure to oxaliplatin suggested a functional role for this Bcl2 family member in the apoptotic cascade initiated by oxaliplatin. To investigate the role of Bax in oxaliplatin-induced apoptosis, we utilised an isogenic HCT116 derivative line that differs only in the absence of a functional Bax gene. Propidium iodide (PI) staining and flow cytometric analysis demonstrated a significant (*P*\<0.03) time- and dose-dependent reduction in the number of apoptotic cells in HCT116 Bax^−/−^ cells compared to isogenic Bax^+/+^ cells following oxaliplatin exposure ([Figure 5A and B](#fig5){ref-type="fig"}Figure 5Role of Bax in sensitivity of colon cancer cells to oxaliplatin. (**A**) Percentage of apoptotic cells following exposure of HCT116 Bax^+/+^ and Bax^−/−^ to the indicated concentrations of oxaliplatin for 72 h is shown. (**B**) Induction of apoptosis in isogenic Bax proficient and deficient HCT116 cells after exposure to 20 *μ*[M]{.smallcaps} oxaliplatin at various times is shown. (**C**) Number of cells with a cytoplasmic cytochrome *c* staining pattern (per 200 cells) following exposure to 20 *μ*[M]{.smallcaps} oxaliplatin for 24 h. In all cases, the mean of three experiments±s.e. of the mean is shown. ^\*^*P*\<0.05; ^\*\*^*P*\<0.01 (Student\'s *t*-test).). In agreement with this observation, HCT116 Bax^−/−^ cells treated with 20 *μ*[M]{.smallcaps} oxaliplatin for 24 h showed a significant (*P*=0.03) reduction compared to isogenic Bax^+/+^ cells in the number of cells with the cytosolic staining pattern of cytochrome *c* characteristic of apoptotic cells ([Figure 5C](#fig5){ref-type="fig"}), further demonstrating an important functional role of Bax in oxaliplatin-induced apoptosis.

Oxaliplatin-induced apoptosis is not dependent upon Fas/FasL association in HCT116 cells
----------------------------------------------------------------------------------------

Bax relocalisation to the mitochondria, accumulation of cytochrome *c* in the cytoplasm and Caspase 3 activation are all events consistent with an intrinsic pathway of activation of apoptosis by oxaliplatin. To investigate the contribution of the extrinsic pathway in oxaliplatin-induced apoptosis, we used antibodies that specifically recognise either the Fas receptor (ZB4) or the Fas ligand (NOK-1) and disrupt Fas/FasL association and the subsequent induction of apoptosis by this pathway. Preincubation of HCT116 cells with either ZB4 or NOK-1 antibodies was effective in preventing apoptosis induced by recombinant human soluble Fas ligand (rhFasL; [Figure 6A](#fig6){ref-type="fig"}Figure 6(**A**) Role of Fas/FasL association in oxaliplatin-induced apoptosis. Exposure of HCT116 to either recombinant human Fas ligand (rhFasL) or oxaliplatin resulted in significant induction of apoptosis. Preincubation with antibodies that prevent Fas/FasL association (ZB4 or NOK-1) for 1 h prevented apoptosis induced by rhFasL but had no effects on oxaliplatin-induced apoptosis. Mean of three experiments±s.e. (**B**) Effects of oxaliplatin treatment in p53 levels. Western blot analysis demonstrated that exposure of HCT116 cells to 10 *μ*[M]{.smallcaps} oxaliplatin results in increased levels of p53 and the cdk inhibitor p21^waf1/cip1^, a p53 target gene. *β*-Actin levels on a parallel blot are shown as a loading control.). However, pretreatment with ZB4 or NOK-1 antibodies did not affect apoptosis induced by oxaliplatin ([Figure 6A](#fig6){ref-type="fig"}), suggesting that this extrinsic pathway of induction of apoptosis was not activated by oxaliplatin in HCT116 cells.

Role of p53 in the response to oxaliplatin
------------------------------------------

More than 50% of colonic tumours have a mutant p53 gene ([Baker *et al*, 1990](#bib8){ref-type="other"}), and a functional p53 protein has been shown to be important for the cellular response to a variety of proapoptotic stimuli, including chemotherapeutic agents commonly used in the treatment of colorectal cancer, such as 5FU and CPT-11 ([Bunz *et al*, 1999](#bib11){ref-type="other"}; [Arango *et al*, 2001](#bib3){ref-type="other"}; [2003](#bib4){ref-type="other"}; [Magrini *et al*, 2002](#bib34){ref-type="other"}). Here, we demonstrate that exposure of wild-type p53 HCT116 cells to oxaliplatin results in increased levels of p53 ([Figure 6B](#fig6){ref-type="fig"}), and consistent with this observation, the p53 target gene p21^waf1/cip1^ was also upregulated ([Figure 6B](#fig6){ref-type="fig"}). The product of the p53 gene is a transcription factor that can either promote apoptosis, through different mechanisms such as Bax upregulation, or induce cell cycle arrest and DNA damage repair by means of the transcriptional upregulation of genes such as p21^waf1/cip1^ and Gadd45. Therefore, we directly tested the role of p53 in the sensitivity of colon cancer cells to oxaliplatin using parental wild-type p53 HCT116 cells and isogenic HCT116 p53^−/−^ cells. Relative to parental cells, p53-deficient HCT116 cells showed a time- and concentration-dependent protection from the apoptotic effects of oxaliplatin ([Figure 7A and B](#fig7){ref-type="fig"}Figure 7Role of p53 in sensitivity of colon cancer cells to oxaliplatin. (**A**) Fold induction of apoptosis in HCT116 p53^+/+^ and HCT116 p53^−/−^ cultures after exposure to 25 *μ*[M]{.smallcaps} oxaliplatin for different times, or (**B**) to different concentrations oxaliplatin for 72 h are shown. (**C**) Comparison of oxaliplatin-induced growth inhibition between HCT116 p53^+/+^ and p53^−/−^ cells. (**D**) Clonogenic potential of HCT116 p53^+/+^ and p53^−/−^ cells treated with 2.5--4 *μ*[M]{.smallcaps} oxaliplatin for 9 h. Values shown are the mean of at least three different experiments±s.e. of the mean.). The reduced apoptotic effects of oxaliplatin in HCT116 p53^−/−^ could be detected after 16 h of treatment as a 10-fold reduction in the number of cells exhibiting Bax translocation and cytochrome *c* release compared to parental HCT116 p53^+/+^ (not shown). Moreover, the concentration of oxaliplatin necessary to cause a 50% growth inhibition (GI~50~) after 72 h of exposure was four-fold higher in HCT116 p53^−/−^ cells compared to parental HCT116 cells (2.04±0.15 and 0.53±0.04 *μ*[M]{.smallcaps} respectively; *P*\<0.0001; [Figure 7C](#fig7){ref-type="fig"}). To investigate the long-term implications of the reduced apoptosis and growth inhibition in response to oxaliplatin in HCT116 p53^−/−^ cells, we assessed the clonogenic potential of parental HCT116 p53^+/+^ and isogenic HCT116 p53^−/−^ cells 2 weeks after exposure to oxaliplatin for 9 h. This assay demonstrated that exposure of parental HCT116 p53^+/+^ cells to concentrations of oxaliplatin ranging from 2.5 to 4 *μ*[M]{.smallcaps}, resulted in up to 70% reduction in the number of cells with long-term clonogenic potential. In contrast, these concentrations of oxaliplatin had no effect on clonogenicity of HCT116 p53^−/−^ cells ([Figure 7D](#fig7){ref-type="fig"}), further demonstrating that inactivation of p53 in colon cancer cells results in a significant protection from oxaliplatin cytotoxicity.

To further investigate the role of p53 in the response of colorectal cancer cells to oxaliplatin, we assessed the sensitivity to this agent in a panel of 30 different colorectal cancer cell lines of known p53 mutational status ([Mariadason *et al*, 2003](#bib37){ref-type="other"}). Of these 30 cell lines, 11 had a wild-type p53 gene, and the remaining 19 exhibited inactivating mutations in this tumour suppressor. Considerable variability was observed among different colorectal cancer cell lines in the number of apoptotic cells following 72 h treatment with 10 *μ*[M]{.smallcaps} oxaliplatin ([Figure 8A](#fig8){ref-type="fig"}Figure 8Microarray-based prediction of response to oxaliplatin. (**A**) Percentage of apoptotic cells following exposure of a panel of 30 colorectal cancer cell lines to 10 *μ*[M]{.smallcaps} oxaliplatin for 72 h. Cell lines with a wild-type p53 gene are indicated (WT). The inset shows the mean percentage apoptosis in p53 wild type and mutant cell lines. Mean of three independent experiments in triplicate±s.e. of the mean is shown. (**B**) Correlation between experimentally observed and expression profile predicted percentage apoptosis following treatment with 10 *μ*[M]{.smallcaps} oxaliplatin for 72 h. The predicted apoptosis value for all 30 cell lines was calculated using the expression profile of the 80 genes best correlated with drug response and a multiple regression model through a leave-one-out cross-validation approach (see Material and Methods).). Despite the clear role of p53 in the apoptotic response to oxaliplatin demonstrated using the HCT116 isogenic system that differs only in the presence or absence of a functional p53 protein, the mutational status of this tumour suppressor gene could not predict the apoptotic response to 10 *μ*[M]{.smallcaps} oxaliplatin ([Figure 8A](#fig8){ref-type="fig"}), suggesting that additional factors modulate sensitivity to this agent.

Response to oxaliplatin can be predicted using the expression profile of untreated colorectal cancer cells
----------------------------------------------------------------------------------------------------------

Due to the great complexity of the molecular mechanisms determining response to oxaliplatin, analysis of the p53 mutational status is likely to be of limited predictive value in the clinical setting. As an alternative approach, we used cDNA microarray analysis to assess the levels of expression of 9216 sequences in the same panel of 30 colorectal cancer cell lines, and used the expression profile of untreated cells to make predictions concerning response to oxaliplatin.

In order to validate the accuracy of the predictions within the panel of 30 cell lines we used a 'leave-one-out' cross-validation approach. Here, one of the 30 samples is held out, and the *N* genes whose expression best correlates with the apoptotic response are selected using the remaining 29 cell lines. The apoptotic response in the 30th line is then estimated using the expression of those *N* genes and a predictor based on a multiple regression model (see Materials and Methods for details). This process is repeated 30 times holding out a different cell line in each iteration. In this way, a predicted value for the apoptotic response to oxaliplatin is obtained for each of the 30 cell lines, which can then be compared to the experimentally observed response to this agent. To optimise the predictive rule, we tested the effect of varying the number of *N* input genes from the 10-best through 200-best correlated with oxaliplatin-induced apoptosis (see Materials and Methods). This analysis demonstrated that selection of the 80 genes best correlated with oxaliplatin-induced apoptosis produced the most accurate prediction, with a highly significant correlation (*r*=0.53, *P*=0.002) between the observed and estimated response to oxaliplatin ([Figure 8B](#fig8){ref-type="fig"}). Importantly, the correlation between observed and estimated response to oxaliplatin by a group of 80 randomly selected genes was not significant (*P*=0.19). This formally demonstrates that cDNA microarray based expression profiling can be used to predict response to oxaliplatin in colorectal cancer cells.

The 'leave-one-out' cross-validation approach adopted produced a slightly different list of 80 genes in each iteration, as a different cell line is held out in each round of analysis. A total of 254 genes were used in at least one of the 30 cycles, and 28 of them were present in all of the 30 gene lists used ([Table 1](#tbl1){ref-type="table"}Table 1List of 254 genes used at least once in the 30 leave-one-out cross-validation loops**AccessionNameCorrelation^a^Count in LOOCV^b^Biological process (GO)^c^**AA455003General transcription factor IIH, polypeptide 1, 62 kDa−0.7730DNA repairR98008Progestin and adipoQ receptor family member III−0.7030Biological process unknownAA417012Zinc-finger protein 336−0.6730Regulation of transcription, DNA-dependentAA412691Nuclear transcription factor Y, alpha−0.6730Regulation of transcription, DNA-dependentAA030029Protein kinase C, alpha−0.6530Regulation of cell cycleR06567Clone 23907 mRNA sequence−0.6430Biological process unknownAA521025G protein pathway suppressor 1−0.6230JNK cascadeAA405769Phosphoenolpyruvate carboxykinase 1 (soluble)−0.6230GluconeogenesisAA608576Microtubule-associated protein, RP/EB family, member 2−0.6230Cell proliferationAA083385BTB (POZ) domain containing 1−0.6230Biological process unknownW32660RAP2A, member of RAS oncogene family−0.6130Signal transductionR46662RAP2A, member of RAS oncogene family−0.6130Signal transductionH14343Cell division cycle 25B−0.6030M phase of mitotic cell cycleAA480071Transcription factor 7 (T-cell specific, HMG-box)−0.6029Wnt receptor signaling pathwayAA456014Hypothetical protein FLJ20580−0.6030Biological process unknownH099062′,3′-cyclic nucleotide 3′ phosphodiesterase−0.6030Synaptic transmissionN51260KIAA0240−0.6029Biological process unknownH56069Glutamate--cysteine ligase, catalytic subunit−0.5930Cysteine metabolismAA489104Thyroid hormone receptor interactor 3−0.5929Regulation of transcription, DNA-dependentT77959Tripeptidyl peptidase II−0.5929Proteolysis and peptidolysisAA479196General transcription factor IIF, polypeptide 2, 30 kDa−0.5930Transcription initiation from Pol II promoterAA430656Docking protein 4−0.5829Biological process unknownH30688Spectrin, beta, nonerythrocytic 2−0.5829Vesicle-mediated transportR10570Hypothetical protein KIAA1434−0.5828Biological process unknownR54358Ligase IV, DNA, ATP-dependent−0.5727DNA repairH08548ATP citrate lyase−0.5727Coenzyme A biosynthesisAA418811Fibrillin 1 (Marfan syndrome)−0.5726Skeletal developmentAA410591Met proto-oncogene (hepatocyte growth factor receptor)−0.5728Cell proliferationW86653FK506-binding protein 5−0.5627Protein foldingH11501Hypothetical protein BC017169−0.5627TransportAA521490Limkain b1−0.5627Biological process unknownAA447691Pitrilysin metalloproteinase 1−0.5627Activation of MAP/ERK kinase kinaseR42187ESTs−0.5627Biological process unknownH89996CCCTC-binding factor (zinc-finger protein)−0.5627Negative regulation of cell cycleAA148536Nucleoporin 98 kDa−0.5625Intracellular protein transportR01323Microfibrillar-associated protein 1−0.5625Biological process unknownAA425401Serine/threonine kinase 24 (STE20 homolog, yeast)−0.5525Signal transductionT49159Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2−0.5524AntiapoptosisAA001918ESTs−0.5524Biological process unknownN70759KIAA0996 protein−0.5524Biological process unknownAA232979Zinc-finger RNA binding protein−0.5519Biological process unknownAA521232ras-related C3 botulinum toxin substrate 2−0.5520Small GTPase mediated signal transductionAA426311Mesenchyme homeo box 1−0.5521DevelopmentAA074666ESTs−0.5415Biological process unknownAA479888Rabaptin, RAB GTPase binding effector protein 1−0.5414EndocytosisAA701929Bystin-like−0.5415Cell adhesionAA479771KIAA0076−0.5419Biological process unknownR76314ras homolog gene family, member G (rho G)−0.5415Positive regulation of cell proliferationAA004484F-box only protein 9−0.5417Protein modificationAA458840Cell death-regulatory protein GRIM19−0.549ApoptosisAA036974Amine oxidase, copper containing 3−0.549Amine metabolismR28280Solute carrier family 7, member 1−0.5410Amino acid metabolismAA045192Retinoblastoma 1 (including osteosarcoma)−0.538Negative regulation of cell cycleH99215Discs, large homolog 3 (neuroendocrine-dlg, Drosophila)−0.5310Negative regulation of cell proliferationT71757Heme oxygenase (decycling) 1−0.536Heme oxidationAA453175Bridging integrator 1−0.537Negative regulation of cell cycleR12275Hypothetical protein FLJ21827−0.536Biological process unknownAA478524M-phase phosphoprotein 6−0.537M phase of mitotic cell cycleAA434342Proline arginine-rich end leucine-rich repeat protein−0.536Skeletal developmentAA459266Postmeiotic segregation increased 2-like 6−0.535Mismatch repairH49592Guanine nucleotide binding protein (G protein), alpha activating activity polypeptide−0.537G-protein coupled receptor protein signaling pathwayR99749B-cell CLL/lymphoma 6 (zinc-finger protein 51)−0.537Cell growth and/or maintenanceAA621031KIAA0056 protein−0.537Biological process unknownAA232647Zinc-finger protein 161−0.525Regulation of transcription from Pol II promoterAA485214Nucleobindin 2−0.525Biological process unknownAA458973Polymerase (DNA-directed), delta interacting protein 3−0.523Biological process unknownAA608730HBS1-like (*S. cerevisiae*)−0.523Protein biosynthesisH98688ESTs−0.524Biological process unknownAA425908ADP-ribosylation factor interacting protein 2 (arfaptin 2)−0.523Small GTPase mediated signal transductionAA424937Protein kinase C, alpha−0.524Regulation of cell cycleAA017042HIV-1 Tat interactive protein, 60 kDa−0.523Regulation of transcription, DNA-dependentAA284338Chromobox homolog 5 (HP1 alpha homolog, Drosophila)−0.512Chromatin assemblyAA040170Chemokine (C-C motif) ligand 7−0.513Antimicrobial humoral responseAA425089Clock homolog (mouse)−0.514Circadian rhythmN58136Similar to KIAA0393 protein−0.512Biological process unknownR24543Neuroepithelial cell transforming gene 1−0.512Regulation of cell growthR15708Insulin-like 4 (placenta)−0.512Cell proliferationW47073Solute carrier family 20 (phosphate transporter), member 1−0.513Phosphate transportAA703187Solute carrier family 33 (acetyl-CoA transporter), member 1−0.514TransportW79444UBX domain containing 2−0.512Biological process unknownR35292Growth arrest-specific 2 like 1−0.513Cell cycle arrestAA406027CD5 antigen (p56-62)−0.512Cell proliferationW06875Hypothetical protein MGC14816−0.512Biological process unknownR14855F-box only protein 34−0.502Biological process unknownR01451Hypothetical protein KIAA1259−0.501Biological process unknownAA449154Skeletal muscle and kidney enriched inositol phosphatase−0.502Actin cytoskeleton organization and biogenesisH48420Prothymosin alpha−0.501Biological process unknownAA455043Holocarboxylase synthetase−0.502Protein modificationAA232647Zinc-finger protein 161−0.502Regulation of transcription from Pol II promoterR11490Translocated promoter region (to activated MET oncogene)−0.502TransportT58146HLA complex P5−0.502Defense responseH54366KIAA0034 gene, complete cds−0.502Biological process unknownAA406269Nuclear factor I/X (CCAAT-binding transcription factor)−0.502DNA replicationR02346Small nuclear ribonucleoprotein 70 kDa polypeptide (RNP antigen)−0.501RNA splicingH64850Clone 23612 mRNA sequence−0.501Biological process unknownN74574Hypothetical protein MGC9084−0.493Biological process unknownN26645Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)−0.492RAS protein signal transductionR26434Protein phosphatase 1, catalytic subunit, beta isoform−0.491Biological process unknownAA025850Myosin VA (heavy polypeptide 12, myoxin)−0.491TransportH59208ESTs−0.491Biological process unknownAA490721Splicing factor, arginine/serine-rich 9−0.492mRNA splice site selectionR10604Spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomal dominant, ataxin 2)−0.491mRNA splicingR95732DNA (cytosine-5-)-methyltransferase 2−0.491DNA methylationAA149096Hemopoietic cell kinase−0.492Biological process unknownAA489714Chromosome 9 open reading frame 60−0.491Biological process unknownAA045587TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 20 kDa−0.492Regulation of transcription, DNA-dependentAA485443Ring finger protein 41−0.481Biological process unknownAA085676ADP-ribosylation factor guanine nucleotide factor 6−0.481Biological process unknownW58032Frizzled-related protein−0.481Wnt receptor signaling pathwayN71653Aspartoacylase (aminoacylase 2, Canavan disease)−0.482Aspartate catabolismAA004324Hypothetical protein BC007706−0.481Biological process unknownAA441935Achaete-scute complex-like 1 (Drosophila)−0.481Cell differentiationR22050Topoisomerase (DNA) II beta (180kD)−0.481DNA topological changeW31074Fatty-acid-Coenzyme A ligase, long-chain 3−0.483Fatty acid metabolismT72581Matrix metalloproteinase 9−0.483Collagen catabolismAA453105Histone 1, H2ac−0.481Nucleosome assemblyAA988746WD repeat and SOCS box containing protein 2−0.481Intracellular signaling cascadeAA495766Chromosome condensation 1-like−0.481Biological process unknownAA489699COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis)−0.481Biological process unknownT65902Splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor)−0.481mRNA splice site selectionAA446908Kinesin family member 3C−0.471Biological process unknownAA047812Origin recognition complex, subunit 2-like (yeast)−0.471DNA replicationAA452566Peroxisomal membrane protein 3, 35 kDa (Zellweger syndrome)−0.471Peroxisome organization and biogenesisR91948Pantothenate kinase 3−0.471Coenzyme A biosynthesisT52894Myosin light chain 1 slow a−0.471Muscle developmentAA001749Microtubule-associated protein, RP/EB family, member 1−0.471Cell proliferationAA430035Reticulon 3−0.471Biological process unknownN79179Pyruvate dehydrogenase complex, lipoyl-containing component X; E3-binding protein−0.471Biological process unknownR13911T54 protein−0.471Biological process unknownAA447579Hypothetical protein FLJ11101−0.471Biological process unknownAA454639F-box only protein 9−0.471Protein modificationAA476460Protein tyrosine phosphatase, receptor-type, Z polypeptide 1−0.462One-carbon compound metabolismAA147642cDNA: FLJ21949 fis, clone HEP04922−0.461Biological process unknownAA479954Similar to RNA polymerase B transcription factor 3−0.461Biological process unknownN80382Phosphodiesterase 6D, cGMP-specific, rod, delta−0.461Visual perceptionR88246Adrenergic, beta, receptor kinase 1−0.451Signal transductionAA150895Hypothetical protein MGC26690−0.451Biological process unknownAA680407Similar to ubiquitin binding protein−0.451Biological process unknownAA063398Chromosome 15 open reading frame 15−0.451Protein biosynthesisAA459572Protein phosphatase 1, regulatory subunit 7−0.451Biological process unknownAA401429Dynein light chain 2−0.452Microtubule-based processAA434130Thioredoxin reductase 2−0.441Response to oxygen radicalsAA453593BB1=malignant cell expression-enhanced gene/tumor progression-enhanced gene−0.441Protein arginylationT77891ESTs−0.441Biological process unknownN48137Glycophorin E−0.441Biological process unknownN30147CDNA FLJ34899 fis, clone NT2NE2018594.−0.431Biological process unknownAA011185Hypothetical protein FLJ14431−0.431MetabolismN58558Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4−0.431Acute-phase responseAA055221Apoptosis, caspase activation inhibitor−0.431ApoptosisAA280677Zinc-finger protein 258−0.431DevelopmentAA026709Dedicator of cytokinesis 6−0.431Biological process unknownAA487070Similar to CGI-55 protein (LOC152502), mRNA−0.431Biological process unknownAA284282Hypothetical protein FLJ30277−0.431Biological process unknownT57859Natural killer cell group 7 sequence−0.421Biological process unknownAA448001TBP-like 1−0.421Regulation of transcriptionN92085ESTs−0.411Biological process unknownAA423867Multimerin−0.411Blood coagulationAA443302ras homolog gene family, member E−0.381Small GTPase mediated signal transductionH52361ESTs−0.371Biological process unknownAA482198Mannose phosphate isomerase−0.361Carbohydrate metabolismH66030Centrosomal protein 1−0.361Biological process unknownAA458472Major histocompatibility complex, class II, DQ beta 1−0.361Immune responseAA447696Yippee protein−0.351Biological process unknownAA419164Retinoic acid receptor, beta−0.341Cell growth and/or maintenanceAA453849ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1−0.321ATP synthesis coupled proton transportT96688PBX/knotted 1 hoemobox 1−0.321Biological process unknownR41732Mitogen-activated protein kinase 8 interacting protein 10.281Vesicle-mediated transportAA419622Hypothetical protein FLJ101340.311Biological process unknownAA128017Clone DNA100312 VSSW1971 (UNQ1971) mRNA0.331Biological process unknownR23810Full-length insert cDNA YI09H090.331Biological process unknownT90871EST0.351Biological process unknownAA005228ESTs0.391Biological process unknownAA004811ESTs0.391Biological process unknownR54797ESTs, Weakly similar to reverse transcriptase homolog0.391Biological process unknownT95930ESTs0.401Biological process unknownAA058713ESTs0.411Biological process unknownT84865ESTs0.411Biological process unknownN46943GGA binding partner0.411Biological process unknownAA677403Glycoprotein hormones, alpha polypeptide0.421Cell--cell signalingAA872379SMT3 suppressor of mif two 3 homolog 1 (yeast)0.421Biological process unknownT96870ESTs0.421Biological process unknownAA610111Hypothetical protein FLJ218680.431Biological process unknownAA400121A-kinase anchoring protein 280.441Biological process unknownH72319ESTs0.441Biological process unknownH23124Olfactomedin related ER localized protein0.441Biological process unknownAA447515MAX dimerization protein 40.441Negative regulation of cell proliferationN62914EST0.441Biological process unknownT53298Insulin-like growth factor binding protein 70.451Negative regulation of cell proliferationAA421488CDNA FLJ26472 fis, clone KDN045060.461Biological process unknownH93837Apolipoprotein B (including Ag(x) antigen)0.461Lipid transportN78306ESTs0.461Biological process unknownN32502ESTs0.461Biological process unknownAA488672Kruppel-like factor 7 (ubiquitous)0.471Regulation of transcription from Pol II promoterAA053815Hypothetical protein FLJ117670.471Biological process unknownR02716Hypothetical protein FLJ146390.471Biological process unknownAA701545Ribonuclease, RNase A family, k60.471RNA catabolismR93069ESTs0.471Biological process unknownT54121Cyclin E10.482Regulation of cell cycleH57309Snail homolog 2 (Drosophila)0.481DevelopmentT56948Pumilio homolog 1 (Drosophila)0.481Biological process unknownN93191Voltage-dependent calcium channel gamma subunit-like protein0.481Biological process unknownW33154Formin binding protein 10.491Biological process unknownT95113Viperin0.491Biological process unknownAA679177Butyrate-induced transcript 10.492Activation of JUNKW89074ESTs0.491Biological process unknownR97540Down syndrome critical region gene 30.492Intracellular protein transportW60581Brain expressed, X-linked 10.492Biological process unknownAA037352Paired box gene 10.502Biological process unknownT53389Fc fragment of IgG binding protein0.501Biological process unknownN53480Clone IMAGE:4794941, mRNA0.503Biological process unknownAA410604CDC16 cell division cycle 16 homolog (*S. cerevisiae*)0.501Cell cycleN22827Ferredoxin 10.501Steroid metabolismR95893EST0.501Biological process unknownAA872397Lectin, galactoside-binding, soluble, 2 (galectin 2)0.502Heterophilic cell adhesionH72588ESTs0.512Biological process unknownN92048ESTs0.511Biological process unknownN54793ESTs0.513Biological process unknownAA136699ESTs0.511Biological process unknownAA131466Leukemia inhibitory factor receptor0.514Cell surface receptor linked signal transductionN33331Peroxisome proliferative activated receptor, delta0.523Lipid metabolismAA668527Mucosal vascular addressin cell adhesion molecule 10.525Cell adhesionAA677706Lactotransferrin0.523Iron ion transportAA459390Hypothetical protein FLJ221690.536Biological process unknownW02624Kelch repeat and BTB (POZ) domain containing 20.536Biological process unknownAA984940Ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin)0.5311RNA catabolismAA464180X-linked protein0.539Biological process unknownR89765Full-length insert cDNA clone YP91F020.5411Biological process unknownAA102068F-box and leucine-rich repeat protein 80.5413Biological process unknownAA431429ESTs, Weakly similar to A-kinase anchor protein DAKAP550 \[*D. melanogaster*\]0.5420Biological process unknownAA009671ESTs0.5421Biological process unknownAA458965Natural killer cell transcript 40.5519Cell adhesionH51438ESTs0.5524Biological process unknownAA447593Dynein, axonemal, light intermediate polypeptide 10.5526Cell motilityT98717ESTs0.5626Biological process unknownAA485358Seven transmembrane domain protein0.5625Biological process unknownAA022935Formin-like 20.5627Regulation of transcription, DNA-dependentH87770Full-length insert cDNA YI27F120.5625Biological process unknownAA024866Hypothetical protein FLJ327310.5628Biological process unknownAA055992Hypothetical protein MGC177910.5728Biological process unknownR92446Cytokine receptor-like molecule 90.5728Biological process unknownAA443971ESTs0.5729Biological process unknownN79813CDNA FLJ45930 fis, clone PLACE70007070.5928Biological process unknownW80688Zinc finger, CW-type with coiled-coil domain 10.5929Biological process unknownN72185ESTs0.6030Biological process unknownAA136666CDNA: FLJ22750 fis, clone KAIA04780.6030Biological process unknownAA133167KIAA1644 protein0.6030Biological process unknownT84703ESTs0.6130Biological process unknownAA029997Collagen, type IV, alpha 5 (Alport syndrome)0.6230Biological process unknownAA953975Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon0.6230I-kappaB kinase/NF-kappaB cascadeW88801Trans-prenyltransferase0.6330Isoprenoid biosynthesisN70632Alcohol dehydrogenase, iron containing, 10.6530MetabolismAA701081Leucine-rich repeat transmembrane neuronal 2 protein0.6530Biological process unknownW93482LOC374841 (LOC374841), mRNA0.6730Biological process unknownR20886Stanniocalcin 20.6830Cell--cell signaling[^1][^2][^3]). The expression profile of all 9216 genes in the cDNA microarrays used can be found on our website ([www.augenlichtlab.com](http://www.augenlichtlab.com)).

DISCUSSION
==========

The platinum compound oxaliplatin is frequently used in the treatment of colorectal cancer patients that are resistant to 5FU, and can also be used in combination with 5FU or CPT-11, improving response rates and progression-free survival ([Levi *et al*, 1993](#bib29){ref-type="other"}; [Bertheault-Cvitkovic *et al*, 1996](#bib9){ref-type="other"}; [Machover *et al*, 1996](#bib33){ref-type="other"}; [de Gramont *et al*, 1997](#bib15){ref-type="other"}; [2000](#bib14){ref-type="other"}; [Andre *et al*, 1999](#bib1){ref-type="other"}; [Maindrault-Goebel *et al*, 1999](#bib35){ref-type="other"}; [Giacchetti *et al*, 2000](#bib22){ref-type="other"}). Oxaliplatin disrupts DNA replication and transcription by forming intrastrand DNA adducts, but the downstream molecular events underlying the cytotoxic effects of this chemotherapeutic agent have not been well characterised.

Here, we show that exposure of HCT116 colon cancer cells to clinically relevant concentrations of oxaliplatin ([Ehrsson *et al*, 2002](#bib19){ref-type="other"}; [Tassone *et al*, 2002](#bib50){ref-type="other"}) greatly reduced the long-term clonogenic potential of these cells (solid line in [Figure 7D](#fig7){ref-type="fig"}). This was associated with an arrest of proliferating cells in the G2/M phases of the cell cycle ([Figure 1](#fig1){ref-type="fig"}). Consistent with this observation, there was a significant reduction in the growth rate of oxaliplatin-treated cells compared to control untreated cells (solid line in [Figure 7C](#fig7){ref-type="fig"}). Importantly, exposure of HCT116 cells to oxaliplatin resulted in a significant induction of apoptosis detectable as early as 24 h after treatment with the lowest concentration assessed (see [Figure 2C](#fig2){ref-type="fig"}). Although impairment of the growth of tumour cells is an important component contributing to the overall response to chemotherapy, cell death is the preferred method of elimination of malignant cells, since this is a terminal and irreversible mechanism. Clonal selection of tumour cells frequently results in the acquisition of mechanisms of evading apoptosis. Therefore, understanding of the molecular mechanisms involved in the induction of apoptosis after exposure to chemotherapeutic agents is important for two reasons: first, it can provide information regarding pathways that may be modulated to improve treatment efficacy, and second, it can lead to the identification of markers capable of predicting the probability of response to treatment.

In this study we demonstrate that exposure of four different colorectal cancer cells (HCT116, RKO, RW2982 and SW403) to oxaliplatin resulted in recruitment of Bax to the mitochondria, release of cytochrome *c* to the cytosol and Caspase 3 activation. Targeted inactivation of Bax in HCT116 cells resulted in a significant reduction in the number of cells displaying a cytosolic staining pattern of cytochrome *c* and terminal apoptosis following exposure to oxaliplatin. These results demonstrated an important functional role of Bax in the apoptotic cascade of events initiated by exposure to oxaliplatin and are in agreement with previous reports ([Gourdier *et al*, 2002](#bib23){ref-type="other"}; [Hayward *et al*, 2004](#bib25){ref-type="other"}). Moreover, it has been suggested that frameshift mutations in the G8 track of the Bax gene could contribute to the acquisition of resistance to oxaliplatin in HCT116 cells ([Gourdier *et al*., 2002](#bib23){ref-type="other"}). Collectively, these observations suggest the potential of Bax as a genetic marker capable of predicting the probability of response of colorectal cancer patients to this important chemotherapeutic agent.

Bax relocalisation to the mitochondria, release of cytochrome *c* to the cytosol and Caspase 3 activation, are all events consistent with the induction of an intrinsic apoptotic pathway, characterised by the central role of the mitochondria in the initiation of the caspase cascade. Some chemotherapeutic agents, however, induce an apoptotic response through activation of the extrinsic pathway by promoting Fas receptor/Fas ligand association, which in turn leads to the formation of the death-inducing signaling complex (DISC) and the autocatalytic activation of pro-caspase 8. To investigate the contribution of this pathway to oxaliplatin-induced apoptosis, we utilised antibodies that bind to Fas or FasL, thus preventing the association of these two proteins. Although abrogation of Fas/FasL association completely prevented apoptosis induced by recombinant human Fas ligand, it had no effect on oxaliplatin-induced apoptosis, suggesting the predominance of the intrinsic pathway in the apoptotic program initiated by oxaliplatin exposure in HCT116. However, [Marchetti *et al* (2004](#bib36){ref-type="other"}) have recently demonstrated the involvement of the extrinsic pathway in oxaliplatin-induced apoptosis in HCT15 colon cancer cells, suggesting that the role of this pathway may be tumour dependent.

Considerable progress has been made in the identification of genetic markers allowing prediction of colorectal cancer response to 5-FU and CPT-11, which together with oxaliplatin are commonly used for the treatment of these patients ([Augenlicht *et al*, 1997](#bib7){ref-type="other"}; [Bunz *et al*, 1999](#bib11){ref-type="other"}; [Salonga *et al*, 2000](#bib44){ref-type="other"}; [Arango and Augenlicht, 2001](#bib2){ref-type="other"}; [Arango *et al*, 2001](#bib3){ref-type="other"}; [2003](#bib4){ref-type="other"}). However, despite recent efforts ([Arnould *et al*, 2003](#bib5){ref-type="other"}; [Rakitina *et al*, 2003](#bib43){ref-type="other"}) it is currently not possible to accurately predict response to oxaliplatin. p53 is mutated in over 50% of colorectal tumours, and the mutational status of this tumour suppressor has been shown to increase or decrease tumour sensitivity to a number of chemotherapeutic agents. Here we show that oxaliplatin-induced apoptosis was associated with upregulation of p53 protein levels, detectable within 6 h of treatment. This suggested a role of p53 in the apoptotic cascade initiated by oxaliplatin. Using an isogenic system we showed that targeted inactivation of p53 resulted in a four-fold increase in the GI~50~, reduced apoptosis and induced a significant increase in clonogenic potential after exposure to oxaliplatin, demonstrating that inactivation of p53 can lead to significantly increased resistance to oxaliplatin.

However, there are some reports showing that p53 inactivation does not lead to increased resistance to oxaliplatin ([Seo *et al*, 2002](#bib47){ref-type="other"}; [Petit *et al*, 2003](#bib42){ref-type="other"}), suggesting that the role of p53 in the cellular response to oxaliplatin may be tumour dependent. To further investigate the role of p53 in sensitivity of colorectal cancer cells to oxaliplatin, we used a panel of 30 different cell lines of known p53 mutational status. We measured the induction of apoptosis following exposure of these 30 cell lines to clinically achievable doses of oxaliplatin, and found that cell lines with a wild type and mutant p53 gene did not significantly differ in their apoptotic response to oxaliplatin (see [Figure 8A](#fig8){ref-type="fig"}). Similar disparities have been reported for the role of p53 in 5FU response, depending upon whether isogenic cell lines or panels of colorectal cell lines were studied ([Yang *et al*, 1996](#bib52){ref-type="other"}; [Bunz *et al*, 1999](#bib11){ref-type="other"}; [Violette *et al*, 2002](#bib51){ref-type="other"}). Therefore, despite the clear role of p53 in the response of colon cancer cells to oxaliplatin demonstrated using the HCT116 isogenic system, the multiple genetic and epigenetic differences that exist between tumours are likely to affect numerous pathways, thus modulating sensitivity to oxaliplatin. This could limit the clinical value of p53 and other single markers of response to treatment.

Simultaneous analysis of several independent markers predicting response to drug treatment has been shown to be advantageous over single markers ([Salonga *et al*, 2000](#bib44){ref-type="other"}; [Arango *et al*, 2001](#bib3){ref-type="other"}). Microarray analysis provides the means of assessing the levels of expression of thousands of genes simultaneously, and we and others have recently demonstrated that the expression profile of untreated tumour cells can be used to predict response of tumour cells to different chemotherapeutic agents *in vitro* and *in vivo* ([Scherf *et al*, 2000](#bib45){ref-type="other"}; [Kihara *et al*, 2001](#bib28){ref-type="other"}; [Zembutsu *et al*, 2002](#bib53){ref-type="other"}; [Mariadason *et al*, 2003](#bib37){ref-type="other"}). Here, we used a cDNA microarray-based approach to measure the expression levels of 9216 transcripts in a panel of 30 colorectal cancer cell lines for which the sensitivity to oxaliplatin was also assessed. The profile of expression of the 80 genes best correlated with sensitivity was used to predict the quantitative apoptotic response to oxaliplatin in these 30 cell lines. Using a 'leave-one-out' cross-validation approach we demonstrated a highly significant correlation between experimentally observed and microarray-predicted apoptotic response to oxaliplatin (*R*=0.53, *P*=0.002).

Our microarray experiments identified a number of genes and expressed sequence tags (ESTs) that are differentially expressed in cell lines that are sensitive and resistant to oxaliplatin. Among the 254 transcripts that were used in at least one of the 30 'leave-one-out' cross-validation loops, several of them have a known role in apoptosis ([Table 1](#tbl1){ref-type="table"}). The serine/threonine kinase Protein Kinase C alpha (PKC*α*) has been associated with cell survival and the suppression of apoptosis ([Deacon *et al*, 1997](#bib16){ref-type="other"}; [Orlandi *et al*, 2003](#bib40){ref-type="other"}). PKC*α* was represented twice in our cDNA microarray and both probes demonstrated that expression levels were lower in cell lines with a higher apoptotic response to oxaliplatin. This is in good agreement with previous reports demonstrating that PKC*α* levels modulate the cellular response to cisplatin and oxaliplatin ([Johnson *et al*, 2002](#bib26){ref-type="other"}; [Orlandi *et al*, 2003](#bib40){ref-type="other"}). The transcription factor NF*κ*B has been shown to be frequently deregulated in colorectal tumours, and it is associated with increased proliferation and resistance to apoptosis induced by chemotherapeutic agents ([Garg and Aggarwal, 2002](#bib21){ref-type="other"}; [Orlowski and Baldwin, 2002](#bib41){ref-type="other"}). Here we found that the NF*κ*B inhibitor epsilon (NFKBIE) is expressed at higher levels in the more sensitive cell lines. This is consistent with a recent report showing that donwregulation of the transcriptional activity of NF*κ*B significantly sensitises colorectal cancer cells to cytotoxic effects of oxaliplatin ([Rakitina *et al*, 2003](#bib43){ref-type="other"}). In addition, the recently identified apoptosis inhibitor AVEN ([Chau *et al*, 2000](#bib12){ref-type="other"}) was found to be expressed at higher levels in cell lines that showed reduced apoptosis in response to oxaliplatin.

The cytotoxic activities of oxaliplatin are believed to be linked to DNA damage, and the levels of expression of the DNA repair endonuclease ERCC1 (excision repair cross-complementing 1) have been shown to be inversely correlated with response to oxaliplatin ([Shirota *et al*, 2001](#bib48){ref-type="other"}; [Arnould *et al*, 2003](#bib5){ref-type="other"}). Although ERCC1 was not represented in the 9K chips used in this study, our microarray analyses identified at least four genes involved in DNA repair mechanisms that were significantly correlated with the ability of oxaliplatin to induce apoptosis in colorectal cancer cells (see [Table 1](#tbl1){ref-type="table"}). The histone acetyltransferase HTATIP (HIV-1 Tat interactive protein, 60 kDa), postmeiotic segregation increased 2-like 6 (PMS2L6), general transcription factor IIH, polypeptide 1 (GTF2H1), and the DNA ligase LIG4, showed higher levels of expression in cell lines that are more resistant to oxaliplatin treatment. In fact, at least LIG4 has been shown previously to confer resistance to the related platinum compound cisplatin ([Chipitsyna *et al*, 2004](#bib13){ref-type="other"}).

In summary, this study investigates the molecular mechanisms underlying the cytotoxic effects of oxaliplatin in colorectal cancer cells in an attempt to identify different means of predicting response to this chemotherapeutic agent. We demonstrate that exposure of proliferating colorectal cancer cells to oxaliplatin induces a G2/M arrest and a molecular cascade of events consistent with an intrinsic mechanism of apoptosis. Moreover, the cytotoxic effects of oxaliplatin were shown to be Bax and p53 dependent using and isogenic *in vitro* system. Importantly, we demonstrate that the expression profile of untreated tumour cells can be used to predict response to oxaliplatin, and that this approach outperforms the accuracy of p53 mutational status as a predictive marker. The efficacy of this microarray-based approach to predict response to oxaliplatin remains to be confirmed *in vivo*. Collection of tumour samples from suitable patient populations is currently ongoing at our institution to test the value of these approaches, although completion of the study is dependent upon prolonged follow-up periods to assess response to therapy.
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[^1]: Correlation coefficient between expression levels in 30 colorectal cancer cell lines (Ln) and the corresponding proportion of apoptotic cells after 72 h exposure to 10 *μ*[M]{.smallcaps} oxaliplatin (Ln). The correlation of all 9216 genes can be found in our website: [www.augenlichtlab.com](http://www.augenlichtlab.com).

[^2]: Number of times used in the leave-one-out cross-validation process.

[^3]: Biological process from Gene Ontology.
